Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +0.34%54 5-Year Yield-on-Cost % is 3.04 as of Aug. 09, 2026, which is 44% above its 10-year median of 2.11. GuruFocus rates TSE:6090 with a GF Score™ of 54/100 and a GF Value™ of 円798.54 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 58.73% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:6090'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.32 Med: 2.11 Max: 3.04
Current: 3.04
During the past 12 years, Human Metabolome Technologies's highest Yield on Cost was 3.04. The lowest was 1.32. And the median was 2.11.
TSE:6090's 5-Year Yield-on-Cost % is ranked better than 58.73% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.4
vs TSE:6090: 3.04
Human Metabolome Technologies (TSE:6090) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Human Metabolome Technologies 5-Year Yield-on-Cost % Related Terms
TSE:6090 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's 5-Year Yield-on-Cost % falls into.
Human Metabolome Technologies 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Human Metabolome Technologies (TSE:6090) has a 5-Year Yield-on-Cost % of 3.04 as of Aug. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Human Metabolome Technologies and its competitors. This is 44% above median its historical median of 2.11. Over the past decade, Human Metabolome Technologies' 5-Year Yield-on-Cost % has ranged from 1.32 to 3.04. According to the industry distribution chart, Human Metabolome Technologies ranks #26 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 41.3%.
Is Human Metabolome Technologies' 5-Year Yield-on-Cost % too high?
Human Metabolome Technologies' current 5-Year Yield-on-Cost % of 3.04 is 44% above median its 10-year median of 2.11. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 3.04. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.40. Human Metabolome Technologies' value of 3.04 is 26.7% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #26 out of 63 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #26 out of 63 companies for 5-Year Yield-on-Cost %. This puts Human Metabolome Technologies in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.40. Human Metabolome Technologies' value of 3.04 is 26.7% above this benchmark. Historically, Human Metabolome Technologies' own 5-Year Yield-on-Cost % has ranged from 1.32 to 3.04 over the past decade. While the company's 10-year median is 2.11 vs. the industry median of 2.40, Human Metabolome Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.40, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current 5-Year Yield-on-Cost % of 3.04 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current 5-Year Yield-on-Cost % is 3.04, which is 44% above median its own 10-year median of 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円798.54, compared to a current price of 円592.00 — trading 25.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.04, which is 44% above median its 10-year median of 2.11 and 26.7% above the Medical Diagnostics & Research industry median of 2.40. Human Metabolome Technologies' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current 5-Year Yield-on-Cost % is 3.04 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円592.00 is trading 25.9% below its estimated GF Value™ of 円798.54.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
5-Year Yield-on-Cost %: 3.04 (44% above median its 10-year median of 2.11)
GF Value™: 円798.54 vs. price of 円592.00 (25.9% below fair value)
Industry Position: 26.7% above the Medical Diagnostics & Research median (#26 of 63)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
